TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33337811
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy in elderly patients
Study: 33339120
Drug: Eicosapentaenoic Acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic Acid (EPA) treatment
Study: 33339120
Drug: Docosahexaenoic Acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic Acid (DHA) treatment
Study: 33339464
Drug: Children preparing
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children preparing to transition to oral feeding (CwTF)
Study: 33340402
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone levels <8.8 ng/ml on the day of ET
Study: 33340402
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone levels ≥8.8 ng/ml on the day of ET
Study: 33341314
Drug: 24-h urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h urinary creatinine excretion rate (CER)
Study: 33341407
Drug: IV tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV tobramycin (10 mg/kg/d, ≥10 days)
Study: 33341448
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (serum levels <25 nmol/L)
Study: 33341448
Drug: Sufficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient vitamin D levels (serum levels >50 nmol/L)
Study: 33341870
Drug: Cord-blood IgG
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord-blood IgG concentrations ≥1.04 µg/mL for serotype Ia
Study: 33341870
Drug: Cord-blood IgG
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord-blood IgG concentrations ≥1.53 µg/mL for serotype III
Study: 33341870
Drug: Maternal sera
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal sera IgG threshold ≥2.31 µg/mL for serotype Ia
Study: 33341870
Drug: Maternal sera
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal sera IgG threshold ≥3.41 µg/mL for serotype III
Study: 33341883
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral PrEP (emtricitabine 200 mg/tenofovir diphosphate 300 mg) administered for 12 weeks
Study: 33342078
Drug: Topical pain
Normalized name: Flex24 Topical Pain Patch
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical pain medication
Study: 33343498
Drug: Motor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor therapy
Study: 33344227
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil
Study: 33344752
Drug: Intravenous allopregnanolone
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous allopregnanolone (2 mg, 4 mg, 6 mg, and 10 mg) administered once-per-week for 12 weeks
Study: 33344752
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once-per-week for 12 weeks
Study: 33344752
Drug: Intravenous allopregnanolone
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous allopregnanolone (various dosages)
Study: 33344885
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to Brain Trauma Foundation guidelines
Study: 33345095
Drug: Antioxidant-rich foods;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-rich foods; specific dosage and duration not available.
Study: 33345877
Drug: Ratio of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin
Study: 33345934
Drug: Personal gestational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal gestational weight gain goal consistent with Institute of Medicine recommendations
Study: 33345967
Drug: Invu system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invu system (wireless, wearable, self-administered device)
Study: 33346007
Drug: PPI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI therapy (pantoprazole 40 mg once daily for 4 weeks)
Study: 33346007
Drug: PPI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI therapy in HVs
Study: 33346428
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) prescribed in 28.3% of cases; 90.2% of patients with UGI bleeding received PPI.
Study: 33346428
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy for 6-12 months after elective PCI.
Study: 33346510
Drug: Indirect cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect cold atmospheric plasma (CAP) treatment for 3 months
Study: 33346510
Drug: Indirect cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect cold atmospheric plasma (CAP) treatment for 6 months
Study: 33346510
Drug: Investigator's assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's assessment of indirect CAP treatment
Study: 33347715
Drug: 225Ac-labeled CD33-targeting
Normalized name: 225Ac-HuM195
DrugBank: Lintuzumab satetraxetan AC-225 (DB15053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225Ac-labeled CD33-targeting antibody
Study: 33348999
Drug: Statins (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (specific type, dosage, and duration not available)
Study: 33348999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (specific treatment or placebo not available)
Study: 33349123
Drug: CAR T
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T cell therapy combined with oncolytic viruses (OVs)
Study: 33350618
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 20% albumin at 3 mL/kg over 30 minutes
Study: 33351103
Drug: α-1-antitrypsin (AAT)
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-1-antitrypsin (AAT) treatment
Study: 33351775
Drug: Home-use smell
Normalized name: egg shell membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-use smell and taste test kit for daily self-assessments over 28 days
Study: 33352201
Drug: Copanlisib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (60 mg) + Gemcitabine (1000 mg/m²)
Study: 33352296
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral therapy
Study: 33354862
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 50 mg twice daily for 52 weeks
Study: 33355238
Drug: MK-4166 900
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4166 900 mg i.v. every 3 weeks as monotherapy
Study: 33355238
Drug: MK-4166 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4166 with pembrolizumab 200 mg i.v. every 3 weeks for ≤35 doses
Study: 33355273
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban
Study: 33355914
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg (DTG)-based regimen
Study: 33355914
Drug: Low-dose Efavirenz
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Efavirenz 400 mg (EFV400)-based regimen
Study: 33356019
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 100-mg glasdegib dose under fasted conditions
Study: 33357452
Drug: Immunogenic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunogenic chemotherapy combined with checkpoint blockade
Study: 33358103
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with aortic endoprosthesis
Study: 33359404
Drug: Standard second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard second-line doublet chemotherapy plus a targeted agent
Study: 33360365
Drug: Mobile-enhanced family-focused
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile-enhanced family-focused therapy (FFT) with a mobile app (12 sessions in 18 weeks)
Study: 33361296
Drug: Fluconazole (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (dosage not specified) as prophylaxis or treatment
Study: 33361296
Drug: Fluconazole (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (dosage not specified)
Study: 33361303
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) administered in standard 3-day courses at 4- to 8-week intervals from the second trimester until delivery.
Study: 33362485
Drug: Ketamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine treatment for AUD, specific dosage and duration not mentioned.
Study: 33369580
Drug: PARP inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitors (PARPi)
Study: 33371015
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests (VIA, Gynocular, HR-HPV)
Study: 33371020
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) therapy
Study: 33371779
Drug: 1% IQP-0528
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% IQP-0528 gel (10 mL rectal dose)
Study: 33373024
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (ET) in OAC patients
Study: 33373873
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor (EGFR) inhibition
Study: 33373873
Drug: Drugs inhibiting
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs inhibiting TNF
Study: 33374003
Drug: Nephritogenic IgG2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephritogenic IgG2 antibodies
Study: 33376109
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment for 6 months at plasma concentration levels of 5-8 µg/L
Study: 37153086
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment for 6 months
Study: 33376169
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP level (>10 mg/L) at discharge
Study: 33376169
Drug: Low CRP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low CRP level (≤10 mg/L) at discharge
Study: 33376179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical, functional and circulating biomarkers
Study: 33376186
Drug: Masculinising testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Masculinising testosterone treatment
Study: 33376319
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step count measurement using an activity monitor over 14 consecutive days.
Study: 33377134
Drug: PD-1 x
Normalized name: Pd-1 x ctla-4 dual checkpoint inhibitor xmab20717
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 x CTLA-4 bispecific DART molecule (MGD019)
Study: 33377134
Drug: Combination immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immunotherapy with antibodies directed against PD-1 and CTLA-4
Study: 33377134
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents (PD-1 or CTLA-4 antibodies)
Study: 33378384
Drug: High-dose fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluticasone propionate
Study: 33378384
Drug: Both low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both low and high-dose ICS
Study: 33380478
Drug: Intraocular pressure-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular pressure-lowering therapy (specific details not provided)
Study: 33380478
Drug: Detailed ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed ophthalmic examinations (specific details not provided)
Study: 33382032
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure therapy; Treatment adherence rate: 55% at 1 year.
Study: 33382032
Drug: Positional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positional therapy and opioids/sedative reduction; Treatment received by the rest of the patients with sleep apnea.
Study: 33382032
Drug: Not applicable;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable; High refusal rate for treatment.
Study: 33382405
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiated on the day of enrollment for 171 (87.7%) participants.
Study: 33382405
Drug: Nonreactive or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonreactive or indeterminate HIV antibody on the Geenius assay combined with ARCHITECT S/CO ≥10.
Study: 33383350
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of testosterone cypionate intramuscularly every 28 days concurrent with a luteinising hormone-releasing hormone agonist/antagonist
Study: 33383350
Drug: bipolar androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: bipolar androgen therapy (BAT)
Study: 33385020
Drug: Probiotics; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics; specific dosage and duration not available
Study: 38870745
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events (TRAEs)
Study: 33388360
Drug: External Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Radiation Therapy
Study: 33388985
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant fitting methodology and parameters
Study: 33389209
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of various normalization methods
Study: 33389388
Drug: Ulixertinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulixertinib (10 to 900 mg in dose escalation cohort, 600 mg in 21-day cycles in expansion cohort)
Study: 33389459
Drug: Low salt-low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low salt-low protein diet (0.6 g/kg-day) supplemented with keto-analogues (sLPD) under intensive nutritional counselling
Study: 33389656
Drug: Carfilzomib (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (27 mg/m²) administered twice weekly
Study: 33390782
Drug: RIST treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST treatment protocol (combination of Rapamycin and Dasatinib with Irinotecan and Temozolomide)
Study: 33391002
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 5% dextrose water
Study: 33391002
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 5% dextrose water
Study: 33391002
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 5% dextrose water
Study: 33392485
Drug: INO-4800 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-4800 1.0 mg
Study: 33392485
Drug: INO-4800 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-4800 2.0 mg
Study: 33392541
Drug: Fish oil-containing
Normalized name: fish oil (containing omega-3 acids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil-containing lipid injectable emulsion (Smoflipid 20% lipid emulsion) administered at doses of 1.0 to 1.6 g/kg within 48 hours of enrollment.
Study: 34920917
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg once daily
Study: 33393488
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Nonstatin users (Control)
Study: 33394121
Drug: Higher dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher dietary zinc intake (8.4±4.5 mg/day) from non-red meat sources
Study: 33399311
Drug: PrEP maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP maintenance (87% adherence to 4+ doses per week)
Study: 33399372
Drug: mini-fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini-fluid challenge (mini-FC) of 100 ml over 1 min
Study: 33399383
Drug: 50% inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% inhaled N2O
Study: 33399383
Drug: 25% inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% inhaled N2O
Study: 33399511
Drug: MRI-guided focused
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided focused ultrasound-induced BBB opening targeting the hippocampus and entorhinal cortex, performed three times at 2-week intervals using a 220-kHz transducer and intravenous microbubble contrast agent.
Study: 33400777
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral agents (DAA) treatment
Study: 33402222
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules) during lifestyle intervention
Study: 33402222
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of brown flaxseed and hesperidin
Study: 33402692
Drug: SSTR2 targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSTR2 targeting using PEN-221, a cytotoxic drug conjugate.
Study: 33403007
Drug: nal-IRI 50
Normalized name: IRIS TENAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: nal-IRI 50 mg/m² with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin, administered in three cycles before and three cycles after surgical resection
Study: 33403401
Drug: Drugs used
Normalized name: DRUGS USED IN DIABETES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs used to prevent CIPN (B vitamins, calcium and magnesium infusion)
Study: 33403401
Drug: Therapeutic adjustment
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic adjustment of neurotoxic anticancer drugs
Study: 33403831
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonist (MRA) added to conventional anti-failure therapy
Study: 33404519
Drug: 1.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/day entecavir
Study: 33405950
Drug: High EOI
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High EOI MRD with AML-like consolidation therapy
Study: 33405951
Drug: Average-risk treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average-risk treatment group
Study: 33405951
Drug: High-risk treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk treatment group
Study: 33406328
Drug: Sitagliptin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (600 mg every 12 hours starting the day before transplantation until day 14 after transplantation) plus tacrolimus and sirolimus
Study: 33407685
Drug: Fingolimod treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod treatment for 12 months
Study: 33407910
Drug: iACT (app-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: iACT (app-assisted acceptance and commitment therapy)
Study: 33407947
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention (12-weekly sessions on education, physical activity, stress management, coping skills training) followed by 3 months of continued support and 6 months of skill maintenance
Study: 33408796
Drug: Sustained Acoustic
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Acoustic Medicine (SAM) combined with 1% diclofenac ultrasound gel patch
Study: 33409867
Drug: Subcutaneous IgPro20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20 at 25 mL, Volume Cohort
Study: 33409867
Drug: Subcutaneous IgPro20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IgPro20 at 40 mL, Volume Cohort